Differential interactome proposes subtype-specific biomarkers and potential therapeutics in renal cell carcinomas

Basit Öğe Kaydı
dc.authoridAyşegül Çalışkan İşcan / 0000-0003-1887-9167en_US
dc.authorscopusidAyşegül Çalışkan İşcan / 57217079641
dc.authorwosidAyşegül Çalışkan İşcan / GNJ-6483-2022
dc.contributor.authorÇalışkan İşcan, Ayşegül
dc.contributor.authorGülfidan, Gizem
dc.contributor.authorSinha, Raghu
dc.contributor.authorArga, Kazım Yalçın
dc.date.accessioned2021-03-08T13:39:13Z
dc.date.available2021-03-08T13:39:13Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Temel Bilimleri Bölümüen_US
dc.description.abstractAbstract: Although many studies have been conducted on single gene therapies in cancer patients, the reality is that tumor arises from different coordinating protein groups. Unveiling perturbations in protein interactome related to the tumor formation may contribute to the development of effective diagnosis, treatment strategies, and prognosis. In this study, considering the clinical and transcriptome data of three Renal Cell Carcinoma (RCC) subtypes (ccRCC, pRCC, and chRCC) retrieved from The Cancer Genome Atlas (TCGA) and the human protein interactome, the differential protein–protein interactions were identified in each RCC subtype. The approach enabled the identification of differentially interacting proteins (DIPs) indicating prominent changes in their interaction patterns during tumor formation. Further, diagnostic and prognostic performances were generated by taking into account DIP clusters which are specific to the relevant subtypes. Furthermore, considering the mesenchymal epithelial transition (MET) receptor tyrosine kinase (PDB ID: 3DKF) as a potential drug target specific to pRCC, twenty-one lead compounds were identified through virtual screening of ZINC molecules. In this study, we presented remarkable findings in terms of early diagnosis, prognosis, and effective treatment strategies, that deserve further experimental and clinical efforts.en_US
dc.identifier.citationCaliskan, A.; Gulfidan, G.; Sinha, R.; Arga, K.Y. Differential Interactome Proposes Subtype-Specific Biomarkers and Potential Therapeutics in Renal Cell Carcinomas. J. Pers. Med. 2021, 11, 158. https://doi.org/10.3390/jpm11020158en_US
dc.identifier.doi10.3390/jpm11020158en_US
dc.identifier.issue158en_US
dc.identifier.pmid33672271en_US
dc.identifier.scopus2-s2.0-85114077641en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.3390/jpm11020158
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1517
dc.identifier.volume11en_US
dc.identifier.wosWOS:000622701300001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÇalışkan İşcan, Ayşegül
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofJ. Pers. Med.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal Cancersen_US
dc.subjectProtein Interactomeen_US
dc.subjectDiagnostic Biomarkeren_US
dc.subjectPrognostic Biomarkeren_US
dc.subjectVirtual Screeningen_US
dc.subjectDockingen_US
dc.titleDifferential interactome proposes subtype-specific biomarkers and potential therapeutics in renal cell carcinomasen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
29.pdf
Boyut:
1.94 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Eczacılık Temel Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu